Lantheus Holdings, Inc. $LNTH Shares Sold by Strs Ohio

Strs Ohio cut its position in Lantheus Holdings, Inc. (NASDAQ:LNTH) by 4.7% during the second quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 44,200 shares of the medical equipment provider’s stock after selling 2,200 shares during the period. Strs Ohio owned 0.06% of Lantheus worth $3,618,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

Other institutional investors have also recently made changes to their positions in the company. Signaturefd LLC boosted its stake in shares of Lantheus by 36.5% in the first quarter. Signaturefd LLC now owns 434 shares of the medical equipment provider’s stock worth $42,000 after acquiring an additional 116 shares during the last quarter. Quarry LP boosted its stake in shares of Lantheus by 2,350.0% in the first quarter. Quarry LP now owns 490 shares of the medical equipment provider’s stock worth $48,000 after acquiring an additional 470 shares during the last quarter. Hughes Financial Services LLC acquired a new stake in shares of Lantheus in the first quarter worth approximately $81,000. GAMMA Investing LLC boosted its stake in shares of Lantheus by 29.3% in the first quarter. GAMMA Investing LLC now owns 1,316 shares of the medical equipment provider’s stock worth $128,000 after acquiring an additional 298 shares during the last quarter. Finally, AlphaQuest LLC boosted its stake in shares of Lantheus by 252.5% in the first quarter. AlphaQuest LLC now owns 1,653 shares of the medical equipment provider’s stock worth $161,000 after acquiring an additional 1,184 shares during the last quarter. 99.06% of the stock is owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other Lantheus news, insider Rajiv A. Patel sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The stock was sold at an average price of $56.15, for a total value of $188,944,750.00. Following the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. The trade was a 49.18% decrease in their ownership of the stock. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through the SEC website. Also, insider Farallon Partners L. L C/Ca sold 3,365,000 shares of Lantheus stock in a transaction on Wednesday, August 20th. The shares were sold at an average price of $56.15, for a total value of $188,944,750.00. Following the completion of the sale, the insider owned 3,477,227 shares in the company, valued at $195,246,296.05. This represents a 49.18% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Insiders sold 6,812,000 shares of company stock worth $382,427,380 in the last 90 days. Company insiders own 1.50% of the company’s stock.

Lantheus Stock Performance

Shares of Lantheus stock opened at $57.69 on Monday. Lantheus Holdings, Inc. has a one year low of $47.25 and a one year high of $118.21. The company has a market cap of $3.92 billion, a price-to-earnings ratio of 15.34 and a beta of 0.09. The company has a debt-to-equity ratio of 0.49, a quick ratio of 4.07 and a current ratio of 4.29. The business’s 50 day moving average price is $54.14 and its 200 day moving average price is $69.87.

Lantheus (NASDAQ:LNTH) last announced its quarterly earnings data on Tuesday, May 17th. The medical equipment provider reported $0.05 EPS for the quarter. Lantheus had a return on equity of 34.06% and a net margin of 17.82%.The firm had revenue of $92.51 million for the quarter. On average, research analysts predict that Lantheus Holdings, Inc. will post 6.01 EPS for the current year.

Wall Street Analyst Weigh In

A number of brokerages have recently issued reports on LNTH. B. Riley lowered their price target on Lantheus from $109.00 to $84.00 and set a “buy” rating on the stock in a research note on Tuesday, September 16th. JMP Securities lowered their price target on Lantheus from $112.00 to $73.00 and set a “market outperform” rating on the stock in a research note on Thursday, August 7th. The Goldman Sachs Group set a $77.00 price target on Lantheus and gave the stock a “neutral” rating in a research note on Wednesday, October 8th. Weiss Ratings downgraded Lantheus from a “hold (c-)” rating to a “sell (d+)” rating in a research report on Saturday, October 25th. Finally, TD Cowen reduced their price objective on Lantheus from $95.00 to $80.00 and set a “buy” rating on the stock in a research report on Monday, September 15th. Four analysts have rated the stock with a Buy rating, three have given a Hold rating and one has issued a Sell rating to the company. Based on data from MarketBeat.com, the company currently has a consensus rating of “Hold” and an average target price of $74.50.

Lantheus Profile

Lantheus Holdings, Inc develops, manufactures, and commercializes diagnostic and therapeutic products that assist clinicians in the diagnosis and treatment of heart, cancer, and other diseases worldwide. It provides DEFINITY, an injectable ultrasound enhancing agent used in echocardiography exams; TechneLite, a technetium generator for nuclear medicine procedures; Xenon-133, a radiopharmaceutical gas to assess pulmonary function; Neurolite, an injectable imaging agent to identify the area within the brain where blood flow has been blocked or reduced due to stroke; Cardiolite, an injectable Tc-99m-labeled imaging agent to assess blood flow to the muscle of the heart; and PYLARIFY, an F 18-labelled PSMA-targeted PET imaging agent used for imaging of PSMA positive-lesions in men with prostate cancer.